July 9, 2020 / 11:22 AM / a month ago

BRIEF-FDA Grants Priority Review To Merck's Supplemental Biologics License Application For Keytruda (Pembrolizumab) For Second-Line Treatment Of Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma

July 9 (Reuters) - Merck & Co Inc:

* FDA GRANTS PRIORITY REVIEW TO MERCK’S SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR KEYTRUDA® (PEMBROLIZUMAB) FOR SECOND-LINE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

* MERCK & CO INC - FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT , OR TARGET ACTION, DATE OF OCT. 30, 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below